MRK
Merck & Company Inc
Merck & Company Inc historical holders
total: 20
Fairfax Financial Holdings Merck & Company Inc transactions over time
- Total transactions:
- 4
- New positions:
- 2
- Sold out:
- 1
- Added:
- 1
- Held since:
- 2020 Q4
- Held for:
- 22 quarters
- Latest activity:
- 2021 Q1
Prem Watsa has been an institutional investor in Merck & Company Inc (MRK) since at least 2013 Q2. According to 2026 Q1 report, Prem Watsa holds 172,900 shares with a market value of roughly $20.80M representing 1.07% of their equity portfolio. In our earliest available record from 2013 Q2, Fairfax Financial Holdings held 12,000 shares of MRK. Prem Watsa later completely sold out the position and reinvested in MRK again in 2020 Q4. Since at least 2013 Q2, Fairfax Financial Holdings has made 3 more transactions in this position.
Does Prem Watsa still hold MRK?
Yes, Prem Watsa continues to hold Merck & Company Inc (MRK). According to their 2026 Q1 report, they maintain a position of 172,900 shares valued at approximately $20.80M, representing 1.07% of their equity portfolio.
Has Prem Watsa reinvested in MRK after selling?
Yes, Prem Watsa has shown renewed interest in Merck & Company Inc (MRK). After completely selling their position, they reinitiated an investment in 2020 Q4, demonstrating continued conviction in this ticker.
Estimated cost basis*
- Weighted AVG buy price:
- $80.44
MRK transactions history by Fairfax Financial Holdings
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2021 Q1
|
0.46%
|
172,900
|
$77.09
|
$13,329,000
|
+40.68% (+50,000)
|
+0.13%
|
|
2020 Q4
|
0.45%
|
$81.80
|
new
|
|||
|
2015 Q4
|
0.00%
|
$49.33
|
-100% (-12,000)
|
|||
|
2013 Q2
|
0.02%
|
$46.42
|
new or own*
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.